Lv3
270 积分 2023-05-03 加入
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
1天前
已完结
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
1个月前
已完结
An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
3个月前
已完结
Molecular mechanisms underlying nucleotide repeat expansion disorders
5个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
5个月前
已完结
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
7个月前
已完结
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
7个月前
已完结
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
8个月前
已完结
To the Editor—Impact of mavacamten on atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy
8个月前
已完结
AMPLITUDE: A Phase 2/3 Adaptive Trial of Inaxaplin in APOL1-Mediated Kidney Disease
9个月前
已完结
皖公网安备34019202002308
